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Abstract Inclusion body myositis (IBM), the most com-
mon inXammatory myopathy in the elderly, is often resis-
tant to various forms of therapy. Placebo-controlled
treatment trials with high dose intravenous immunoglobu-
lins (IVIG) have shown disease amelioration in some but
not all patients. Here, we present the informative case of a
70-year-old woman with diagnosed inclusion body myosi-
tis that showed progressive muscle weakness without treat-
ment and following immuno-suppressive treatment with
corticosteroids and azathioprine. A trial with low-dose
intravenous immunoglobulins was started at that time. The
patient responded rapidly to low dose IVIG treatment with
amelioration of muscle strength and normalization of CK
serum activities. Our results demonstrate that IBM patients
may respond to low-dose IVIG treatment which has impor-
tant clinical and economic consequences.
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Abbreviations
IVIG Intravenous immunoglobulins
IBM Inclusion body myositis
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Introduction
Inclusion body myositis (IBM) is the most frequent inXam-
matory myopathy in the elderly [1]. The disease typically
progresses slowly and involves mostly the quadriceps mus-
cles, arm Xexors and small muscles of the Wngers. Sponta-
neous stabilization of disease activity has been reported in
the absence of any therapy [2]. Characteristic microscopic
Wndings are typical intramuscular vacuoles and foci of
amyloid as well as immunological features including MHC
I up-regulation and oligoclonally proliferated inWltrating
CD8+ T cells [3]. In general, response to any treatment of
IBM is weak [2]. Placebo-controlled studies showed lim-
ited eVects of high dose (2 g/kg) IVIG therapy in IBM [4,
5]. It has been noted that at least in some patients progres-
sion of disease stopped while others did not respond, result-
ing in a mild overall eVect of IVIG therapy [5]. As a
consequence, Pongratz et al. [6] suggested a 3-month trial
of high-dose (2 g/kg/month) IVIG to identify IVIG
responders among IBM patients.
Case report
A 70-year-old woman was evaluated for progressive mus-
cle weakness and mildly elevated serum creatin-kinase
(CK) activity. CK elevation and muscle weakness contin-
ued following cessation of treatment with a HMG-Co A
reductase inhibitor. Muscle weakness mostly aVected
strength in the quadriceps muscles. There were enhanced
signal intensities in water-sensitive MRI sequences of the
adductor magnus muscle in both legs and of the semimem-
branous muscle in the right leg (not shown). Biopsy of the
right M. adductus magnus showed vacuoles in several
muscle Wbers; some of them appeared as typical ‘rimmed
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several muscle Wbers (Fig. 1a). Together with inWltrating
leukocytes (Fig. 1a), histologic Wndings were most consis-
tent with inclusion body myositis (IBM). Histological alter-
ations indicative of statin-induced myopathy were not
found. Myositis-related serum autoantibodies (Anti Jo-1,
Anti-PM SCL, Anti PL-7, Anti PL-12, Anti-Ku, Anti Mi-2)
were not detected. There was no clinical evidence of viral- or
superimposed systemic autoimmune disease. The diagnosis
of IBM was established. Due to the reported very limited
eYcacy of any immune-modulating therapy and the
reported spontaneous stabilization of IBM disease, no med-
ication was started at that time, and the disease followed
clinically.
However, muscle weakness progressed. The patient was
Wnally unable to leave the house alone and became increas-
ingly depressed. In the end, hospitalization was required
due to intake of a neuroleptic drug with the purpose of sui-
cide.
A therapeutic trial with prednisone/azathioprine (given
at usual doses, prednisone initially 1 mg/kg with tapering
thereafter, azathioprine 2 mg/kg) was started at that time,
but it showed no eVect on quality of life and muscle
strength, although it was associated with mildly decreased
CK serum activity (Fig. 1b). Prednisone/azathioprine treat-
ment was stopped after 6 months due to lack of subjective
and objective signs of improvement. A trial of intravenous
immunoglobulins (IVIG) was initiated at that time.
In the light of rather disappointing eVects of IVIG in
recent studies in IBM (see below), we reduced the standard
trial dose of IVIG from 2 to 0.3 g/kg/day given on two con-
secutive days as a monthly cycle (0.6 g/kg IVIG per
month). The reason for using a lower than normal IVIG
dose was mostly to reduce IVIG-related side eVects in light
of the low probability of clinical success. Within days after
the Wrst infusion, there was an unexpected rapid subjective
amelioration of the muscle strength and trend to ameliora-
tion at the objective level over the next months (Fig. 1c).
Elevated muscle enzymes normalized within 1 month
(Fig. 1b) and since then without exception stay within nor-
mal range for now 12 months after initiation of IVIG ther-
apy. Control MRI scans of the leg muscles now failed to
detect active myositis (not shown). Quality of life improved
remarkably, and the patient remains in remission for now
12 months after initiation of IVIG therapy.
Discussion
The rapid response following initiation of low-dose IVIG
treatment in this patient was highly unlikely representing
spontaneous disease course since the patient was before
followed clinically for several months without any medica-
tion; however, muscle weakness and general condition pro-
gressed. Also, the negative response to a prednisone/
azathioprine trial at usual dosage (initially 1 mg/kg Prednisone
Fig. 1 a Histology of the 
patient’s muscle biopsy 
(M. adductor magnus). Tri-
chrome staining shows a rimmed 
vacuole. Immunohistochemis-
try demonstrates upregulation of 
MHC class I expression on sev-
eral muscle Wbers, and endomy-
sial inWltrates of CD45 
(leukocyte common antigen) 
positive leukocytes. b Serum 
creatin-kinase (CK) activities 
are shown. c Muscle strength of 
knee extension on the right leg is 
indicated at individual time-
points under diVerent therapies123
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inXammatory muscle disease that would clinically respond
to this standard immuno-suppressive regimen. High IVIG
doses require long infusion time or a higher infusion rate,
which is associated with IVIG-related side eVects, such as
fever, chills, headache or skin reactions [7]. For patients
weighing 80 kg, 2 g/kg IVIG equals 160 g IVIG which
would require infusion of 13 large ampoules (12 g each) of
a common IVIG product. This reXects an infusion volume
of 2.6 l and costs of approximately 10,000 US dollars per
month. Thus, reducing the IVIG dose reduces volume load,
infusion time, IVIG-related side eVects and medication
costs.
The immune-suppressive mechanism of high-dose IVIG
is best documented in idiopathic thrombocytopenic purpura
(ITP), where a transient inability of macrophages to opso-
nize immune complexes following IVIG treatment has been
demonstrated [8, 9]. In recent publications, especially the
group of Ravetch [10] has shed new light to the immune-
suppressive eVects of high dose IVIG. First, IVIG acts by
means of the inhibitory IgG receptor. Second, the immune-
suppressive activity is restricted to a small proportion of
IgG whose Fc fragment is sialylated [11]. Sialylated IgG-Fc
can be recombinantly produced and is much more eVective
on a molar basis than conventional IVIG [12]. Finally,
sialylated IVIG mediates its eVects by binding to a receptor
called DC-Sign in humans [13]. IVIG treatment has been
associated with normalization of complement activation in
patients with dermatomyositis [14]. How IVIG may
improve myositis in IBM patients that respond to the treat-
ment is completely unknown. A study analyzing speciW-
cally immune-modulating eVects of IVIG on muscle
inWltrating cells and their respective cytokines demon-
strated very limited eVects in inXammatory muscle diseases
[15]. Myocytes have been shown to express B7-H3, which
might protect myocytes from CD8+ T cell-mediated lysis
[16]. In contrast to many autoimmune conditions, TNF
blockade was associated with high incidence of disease
Xares in inXammatory myopathies [17].
In our patient, IVIG treatment was unexpectedly suc-
cessful in a low-dose regimen which costs approximately
fourfold less than high-dose IVIG. The very rapid decrease
of CK serum activity following the Wrst IVIG application
after a reasonable period of no therapy and a trial with pred-
nisone/azathioprine make it unlikely that the amelioration
was reXecting spontaneous disease course. In addition, a
similar long lasting and unexpectedly good response to a
comparable low-dose IVIG trial has been reported in an
IBM patient [18]. It may be asked whether high dose IVIG
is counterproductive because of temporarily increased
blood viscosity and/or direct toxic eVects of immunoglobu-
lins on the already abnormal myocytes in IBM. Alterna-
tively, the few patients that positively respond to IVIG
therapy in the high dose IVIG trials would probably also
respond to much lower IVIG doses. This would have
important implications for economic reasons and would
likely help reducing IVIG related side eVects. Taken collec-
tively, we propose to conduct a novel prospective con-
trolled clinical trial of the eVectiveness of low-dose IVIG
therapy in IBM patients.
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